Organon and Co (OGN) - News Archive

In a significant development for the pharmaceutical sector, the European Commission (EC) has granted market authorization for BILDYOS and BILPREVDA, two biosimilar versions of Denosumab sourced from Henlius Biotech, Inc...

In a significant stride for the biotechnology sector, the European Commission (EC) has granted market authorization for two new biosimilars, BILDYOS and BILPREVDA, developed by Shanghai Henlius Biotech, Inc. and Organon...

In a significant development within the pharmaceutical industry, the European Commission recently granted marketing authorization for two biosimilars, BILDYOS and BILPREVDA, both of which are versions of the established...

Organon & Co., a notable player in the biopharmaceutical sector, is currently facing significant legal challenges as a class action lawsuit has been filed against the company. This litigation, spearheaded by prominent l...

Organon Shareholder Alert: Investors Urged to Act Amid Class Action Lawsuit Due to Underperformance In a noteworthy development for shareholders of Organon & Co. (NYSE: OGN), ClaimsFiler has issued a reminder to investo...

In a significant development that has garnered considerable attention in the pharmaceutical and investment communities, Organon & Co. (NYSE: OGN), a renowned healthcare company, faces a class action lawsuit amid financi...

Henlius and Organon Take Significant Leap in Oncology with EMA Validation of Biosimilar HLX11 for HER2-Positive Breast Cancer In a significant development for oncology therapeutics, the European Medicines Agency (EMA) h...

FDA Accepts Biologics License Application for HLX14, a Biosimilar to PROLIA/XGEVA, Marks a Significant Move in Osteoporosis Treatment XANGAI, China, and JERSEY CITY, N.J. In a landmark development for the biosimilar lan...

Shanghai Henlius Biotech, Inc. a leading biotechnology company, in collaboration with Organon, a global healthcare company focusing on women’s health, recently announced a significant milestone in the field of oncology...

Breaking New Ground in HER2-Positive Breast Cancer Treatment: Henlius HLX11 Competes with Perjeta In the ever-evolving landscape of oncology, the quest for innovative therapeutic options continues to be driven by the ch...

In a strategic move to enhance its market presence in the area of migraine treatment, Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, has announced the expansion of its commercial agreem...

: Organon, a global healthcare company focused on women s health, is expanding its market presence through strategic partnerships and regulatory breakthroughs. Recently, it has broadened its commercialization agreement...

Year to date, Organon And Co shares have outperformed the market, showcasing the company s significant growth and market strength. This article aims to interpret recent articles and shed light on the factors behind Orga...

In the volatile landscape of pharmaceutical investments, Organon and Co has demonstrated a commendable resilience in the face of market frustrations. This article examines the recent events surrounding Organon and Co s...

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have announced that the European Medicines Agency (EMA) has validated their marketing authorization applications (MAA) for HLX14, an investigational biosi...

Henlius and Organon s Biosimilar HLX14 for Prolia and Xgeva Validated by EMAShanghai Henlius Biotech, Inc. and Organon have recently announced that the European Medicines Agency (EMA) has validated their marketing autho...

: The European Medicines Agency (EMA) has validated the Marketing Authorization Applications (MAAs) for HLX14, a biosimilar of denosumab, used under the brand names Prolia and Xgeva, developed by Shanghai Henlius Biotec...

The Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have recently announced that the European Medicines Agency (EMA) has validated their marketing authorization applications (MAA) for HLX14. This ground...

EMA Validates Marketing Authorization Applications for Henlius and Organon s Biosimilar Candidate to Prolia and Xgeva Shanghai, China & Jersey City, N.J. Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN)...

Organon, a global healthcare company specializing in women s health, has made a significant announcement today regarding a proposed $1.0 billion senior notes offering. This move reflects Organon s focused efforts to str...